SgIGSF (spermatogenic immunoglobulin superfamily) is a recently identified intercellular adhesion molecule of the immunoglobulin superfamily. In a mast-cell cDNA library, we found a clone that resulted from the retention of intron 7 within the mature SgIGSF message. This clone was predicted to encode a soluble isoform of SgIGSF (sSgIGSF) with 336 amino-acid residues because its open reading frame ended just before the transmembrane domain. We constructed a plasmid expressing sSgIGSF fused to the human IgG Fc fragment at its C-terminus (sSgIGSF-Fc), and transfected it into COS-7 cells. The fusion protein was readily detectable in the culture supernatant. Solid-phase binding assay showed that sSgIGSF interacted directly the extracellular domain of membrane-bound SgIGSF (mSgIGSF). We next examined whether this interaction inhibited homophilic binding of mSgIGSF by aggregation assays using L cells that did not express mSgIGSF. A stable L-cell clone that overexpressed mSgIGSF aggregated with each other but not with mock-transfected L cells, indicating that a homophilic interaction of mSgIGSF mediated the aggregation. Addition of sSgIGSF-Fc inhibited the aggregation of L cells overexpressing mSgIGSF in a dose-dependent manner. Moreover, FACScan analyses revealed the specific binding of sSgIGSF-Fc to mSgIGSF expressed in L cells. Binding of sSgIGSF-Fc to mSgIGSF appeared to inhibit homophilic interactions of mSgIGSF.
SgIGSF (spermatogenic immunoglobulin superfamily) is a recently identified intercellular adhesion molecule of the immunoglobulin superfamily. In a mast-cell cDNA library, we found a clone that resulted from the retention of intron 7 within the mature SgIGSF message. This clone was predicted to encode a soluble isoform of SgIGSF (sSgIGSF) with 336 amino-acid residues because its open reading frame ended just before the transmembrane domain. We constructed a plasmid expressing sSgIGSF fused to the human IgG Fc fragment at its C-terminus (sSgIGSF-Fc), and transfected it into COS-7 cells. The fusion protein was readily detectable in the culture supernatant. Solid-phase binding assay showed that sSgIGSF interacted directly the extracellular domain of membrane-bound SgIGSF (mSgIGSF). We next examined whether this interaction inhibited homophilic binding of mSgIGSF by aggregation assays using L cells that did not express mSgIGSF. A stable L-cell clone that overexpressed mSgIGSF aggregated with each other but not with mock-transfected L cells, indicating that a homophilic interaction of mSgIGSF mediated the aggregation. Addition of sSgIGSF-Fc inhibited the aggregation of L cells overexpressing mSgIGSF in a dose-dependent manner. Moreover, FACScan analyses revealed the specific binding of sSgIGSF-Fc to mSgIGSF expressed in L cells. Binding of sSgIGSF-Fc to mSgIGSF appeared to inhibit homophilic interactions of mSgIGSF. Keywords: IGSF4; TSLC1; homophilic binding; splicing SgIGSF (spermatogenic immunoglobulin superfamily) is a member of the immunoglobulin superfamily that was recently cloned from a cDNA library of adult mouse testes (Wakayama et al., 2001) . Its human orthologue is TSLC1 (tumor suppressor in lung cancer-1), which was originally cloned from a genomic region that frequently exhibits loss of heterozygosity in human lung cancers and which possesses tumorsuppressor activity Pletcher et al., 2001) . The proteins have 98% amino-acid identity with each other , and both have an extracellular domain with significant homology to NCAM-1 (neural cell adhesion molecule-1) and NCAM-2. They also bear a motif sequence in their intracellular domains that putatively connects to the actin cytoskeleton .
Consistent with these structural features, recent studies of Masuda et al. (2002) and of our own (Ito et al., 2003a) have shown that TSLC1 and SgIGSF mediate intercellular adhesion. Both proteins appear to function as homophilic adhesion molecules, because cells overexpressing either SgIGSF or TSLC1 frequently form aggregates, and SgIGSF and TSLC1 localize to the plasma membrane in cell-cell contact areas. In addition, we have shown that SgIGSF is used by mast cells to adhere to fibroblasts (Ito et al., 2003a) and by spermatogenic cells to adhere to Sertoli cells (Wakayama et al., 2003) . In these cases, SgIGSF appears to function as a heterophilic adhesion molecule, because SgIGSF expression is readily detectable in mast and spermatogenic cells but not in fibroblasts and Sertoli cells.
Several adhesion molecules of the immunoglobulin superfamily give rise to soluble forms that contain only their extracellular domains. This is achieved either by protease-mediated cleavage of the extracellular domains near the plasma membrane (Pigott et al., 1992; Hahne et al., 1994) or by alternative splicing of mRNA transcribed from a single gene (Budt et al., 2002; Lee et al., 2003) . Soluble forms often inhibit the adhesive functions of the corresponding membrane-bound forms by binding to their extracellular domains (Kaplan et al., 1993; Meyer et al., 1995; Budt et al., 2002) . Thus, it is postulated that the soluble forms may negatively regulate the binding of adhesion molecules belonging to the immunoglobulin superfamily.
In an attempt to find soluble forms of SgIGSF, we screened a cDNA library of mouse mast cells with an SgIGSF cDNA probe. A total of 16 positive clones were isolated and sequenced. Of these, 15 clones were identical to all or part of the reported sequence of SgIGSF (GenBank accession number AB052293). One clone (#15) contained a unique cDNA insert: its sequence completely matched that of SgIGSF in nucleotides 1-1024 but the following 100-base-long sequence differed from that of SgIGSF. The 100-baselong sequence specific to clone #15 started from the boundary of exons 7 and 8 in the SgIGSF cDNA and ended with an A-repeat sequence. Comparison with the SgIGSF genome revealed that this sequence completely matched the initial 5 0 part of intron 7 (Figure 1 ), indicating that clone #15 resulted from the retention of intron 7 in the mature SgIGSF message. As a result, clone #15 comprised an open reading frame (ORF) that started from the same ATG codon as that of SgIGSF and ended before its transmembrane domain due to the presence of an in-frame stop codon within the sequence contributed by intron 7. Although it was unclear whether the A-repeat sequence located at the 3 0 end of clone #15 was actually used as a poly(A) signal, we denoted the protein encoded by clone #15 as sSgIGSF, as it might be a soluble isoform of SgIGSF. We then denoted the previously reported membrane-bound form as mSgIGSF.
Structural similarities between the SgIGSF and TSLC1 genes suggest that the TSLC1 gene might produce a soluble isoform similar to sSgIGSF. In fact, the genomic sequences of TSLC1 and SgIGSF completely match each other for 19 nucleotides upstream and 15 nucleotides downstream from the exon 7-intron 7 boundary. Thus, if intron 7 were retained in the mature TSLC1 message, the resulting transcript would comprise an ORF similar to that of clone #15. We denoted the protein encoded by this ORF as sTSLC1 and the previously reported membrane-bound form as mTSLC1. The expected sequences of sSgIGSF and sTSLC1 were both 336 amino acids long and completely matched the extracellular part of the corresponding membrane-bound forms except for two amino acids at their C-termini.
By RT-PCR, we examined whether cells and tissues actually contain sSgIGSF and sTSLC1 mRNA. One forward (F1) and three reverse (R1, R2, and R3) primers were designed so as to amplify the entire coding regions of sSgIGSF and sTSLC1 (Figure 2a ). When total RNA from mouse mast cells and lungs was examined by RT-PCR using a primer combination of F1, R1, and R2, bands representing a 1.4-kbp-long mRNA derived from mSgIGSF and a 1.0-kbp-long mRNA derived from Figure 2b ; lane 6). Sequencing revealed that the longer band was derived from mTSLC1 mRNA. The sequence of the shorter band was identical to that expected for sTSLC1. Thus, sSgIGSF and sTSLC1 appear to be physiologically expressed as alternatively spliced variants of SgIGSF and TSLC1, respectively. Two other sets of primers, F2, R2, and R4, and F3, R3, and R5, were used to amplify shorter segments of the mRNAs transcribed from the SgIGSF and TSLC1 genes, respectively ( Figure 2a ). Both primer sets amplified the membrane-bound isoforms more strongly than the soluble isoforms ( Figure 2b ; lanes 3, 5, and 7). This bias was also found when the entire coding regions were RT-PCR-amplified ( Figure 2b ; lanes 2, 4, and 6). The mRNAs of the soluble isoform appeared to be transcribed much less efficiently than the mRNAs of the membrane-bound isoform in mast cells and lungs.
Expression of mSgIGSF and sSgIGSF mRNA was examined in various tissues by RT-PCR using two primer sets, F2 and R4, and F2 and R2, respectively (Figure 2a and c) . Expression of the mSgIGSF mRNA was detectable in all tissues examined (Figure 2c ). Consistent with previous Northern blot analyses (Wakayama et al., 2001; Fukami et al., 2002) , the 
0 -AAATAGCGCCCCAGAATGATGAGCAA-3 0 . The primer sites are indicated along the lines representing the cDNAs of mSgIGSF, sSgIGSF, mTSLC1, and sTSLC1. Open and closed triangles indicate the positions of the start and stop codons, respectively. (b) Detection of transcripts comprising the entire coding regions of sSgIGSF and sTSLC1. Procedures for RNA extraction, RT reactions, and PCR were described previously (Ito et al., 1998) . Primers were used in several combinations as indicated above each lane. The PCR profile consisted of 35 cycles of denaturation at 941C for 30 s, reannealing at 551C for 30 s, and polymerization at 721C for 90 s. PCR products were electrophoresed on 1.2% agarose gels and stained with ethidium bromide. DNA size markers were loaded in the leftmost and rightmost lanes. Bands derived from the membrane-bound isoform mRNA and the soluble isoform mRNA are indicated by arrows and arrowheads, respectively. In some cases, PCR products were cloned into the T/A vector (Novagen) for sequencing. (c) Expression of sSgIGSF mRNA in various tissues. Total RNA was extracted from the various mouse tissues indicated and analysed by RT-PCR using two sets of primers, F2 and R2 (upper), and F2 and R4 (lower), to amplify the mRNAs for mSgIGSF and sSgIGSF, respectively. bActin mRNA was RT-PCR-amplified as described previously (Nakamoto et al., 2001) to verify the equal input of total RNAs. PCR products were electrophoresed on 1.2% agarose gels and stained with ethidium bromide. DNA size markers were loaded in the rightmost lanes. (d) Expression of sTSLC1 mRNA in 14 lung cancers (eight adenocarcinomas and six squamous cell carcinomas). A total of 14 patients with lung cancer underwent surgical operation and two pathologists diagnosed the excised materials according to the International Staging System for Lung Cancer (Mountain, 1997) in Hyogo Medical Center for Adults (Akashi, Japan). Tumor tissues (T) and their adjacent noncancerous lung tissues (N) were sampled from individual patients, as described previously (Ito et al., 2003b) . Total RNA was extracted from these tissues and analysed by RT-PCR using two sets of primers, F3 and R3 (upper) , and F3 and R5 (middle), to amplify mRNAs for mTSLC1 and sTSLC1, respectively. b-Actin mRNA was RT-PCRamplified as described previously (Nakamoto et al., 2001) to verify the equal input of total RNAs (lower) Figure 3 sSgIGSF-Fc is a soluble, N-glycosylated protein. A plasmid vector expressing sSgIGSF-Fc was constructed by PCR using clone #15 as a template with a pair of oligonucleotide primers: F, 5 0 -ACGCGTCGACGGCAGGTGCCCGACATGGC-GAGTGCT-3 0 ; and R, 5 0 -GAAGATCTTACTTACTTTGCG-TACCGTATACATACAGCAT-3 0 . F primer contained an SalI site at the 5 0 end and R primer contained a BglII site at the 5 0 end. The resulting SalI-BglII fragment was inserted into the pEFBos human IgG 1 Fc cassette (pEFBosFc; Suda and Nagata, 1994) via its SalI-BamHI sites. Sequencing confirmed that the obtained plasmid (pEFBosFc-sSgIGSF) expressed the sSgIGSF-Fc protein.
COS-7 cells grown on 60-mm culture dishes were transfected with either the pEFBosFc-sSgIGSF vector or the empty pEFBosFc vector by using the FuGENE regent (Roche Diagnostics). Untransfected COS-7 cells were also cultured. The next day, the cells were washed with phosphate-buffered saline (PBS) and cultured in 2 ml of serum-free Dulbecco's modified Eagle's medium (DMEM) for 48 h. Culture media were passed through a 0.45-mm cellulose acetate filter (Advantec) and 1-ml supernatant aliquots were incubated with protein A-Sepharose beads (Pharmacia) at 41C for 1 h. Precipitates bound to the beads and mouse and human IgG 1 s (1 mg each; Sigma) were separated on 10% SDS-polyacrylamide gels. Prior to electrophoresis, aliquots of the precipitates from the culture of COS-7 cells transfected with pEFBosFcsSgIGSF were treated with PNGase F (New England Biolabs) as described previously (lane 4). Duplicate gels were stained with a silver solution (Daiichi Pure Chemicals Co.) according to the manufacturer's instructions (upper) and blotted with anti-human IgG Fc antibody (Jackson ImmunoResearch Laboratories) (lower)
A soluble isoform of SgIGSF Y-i Koma et al expression levels differed by tissue, that is, the expression was high in brains and testes and low in hearts and kidneys. Similarly, sSgIGSF mRNA was expressed in all tissues examined, and the relative expression levels fluctuated among tissues as mSgIGSF mRNA (Figure 2c ).
Expression levels of mTSLC1 have been shown to decrease in non-small-cell lung cancers Ito et al., 2003b) . We examined whether the mRNA expression for sTSLC1 was also reduced in these tumors. Total RNAs were extracted from cancer lesions and their adjacent noncancerous lung tissues of 14 patients with lung adenocarcinoma or squamous cell carcinoma, and were analysed by RT-PCR using two primer sets, F1 and R5, and F1 and R3 (Figure 2d ). As might be expected, expression levels of the mTSLC1 mRNA were reduced in all cancer lesions. The expression profile of the sTSLC1 mRNA was essentially similar to that of the mTSLC1 mRNA (Figure 2d) . Together with the result of Figure 2c , a certain gene promoter seemed to be commonly used to generate two alternatively spliced transcripts for the membranebound and soluble isoforms of SgIGSF and TSLC1. Interestingly, the magnitude of reduction in mRNA expression for mTSLC1 and sTSLC1 tended to become larger in pathologically advanced cancers. Inactivation of TSLC1 may be an event in the advanced stages rather than the early stages of lung cancers, as Fukami et al. (2003) suggested currently.
To examine whether sSgIGSF is indeed secreted, we transiently transfected COS-7 cells with a plasmid vector that expressed sSgIGSF fused with the human IgG 1 Fc fragment at its C-terminus (sSgIGSF-Fc). As a control, COS-7 cells were either transfected with the empty vector or cultured without transfection. After culturing cells for 48 h in serum-free medium, the cell-free culture supernatants were incubated with protein A-Sepharose beads and proteins bound to the beads were separated on SDS-polyacrylamide gels. Duplicate gels were stained with a silver solution (Figure 3 ; upper) and blotted with an anti-human IgG Fc antibody (Figure 3 ; lower). The results obtained by either method were consistent. A single band of B80 kDa was detected only in the precipitate from the medium of COS-7 cells expressing sSgIGSF-Fc (Figure 3 ; lane 3). When this precipitate was treated with Peptide:N-glycocidase F (PNGase F), the mobility size of the band detected by silver staining and Western blotting decreased to B60 kDa (Figure 3 ; lane 4). The mobility size of deglycosylated sSgIGSF-Fc, B60 kDa, was expected because sSgIGSF consists of 336 amino-acid residues and the Fc fragment consists of 231 amino-acid residues. The recognition specificity of the anti-human IgG Fc antibody was confirmed by blotting mouse and human IgG 1 as a negative and a positive control, respectively (Figure 3 ; lanes 5 and 6). Since sSgIGSF-Fc has the signal peptide sequence of sSgIGSF at its N-terminus and mSgIGSF is heavily glycosylated in its extracellular domain (Ito et al., 2003a) , these results strongly suggest that sSgIGSF is a secreted and heavily glycosylated protein.
Interactions between mSgIGSF and sSgIGSF were examined by the solid-phase binding assay. According to the procedure similar to that for sSgIGSF-Fc purification, the full-length extracellular domain of mSgIGSF was generated as a FLAG-tagged protein (mSgIGSF-ED-FLAG). This protein or FLAG-tagged control protein (bacterial alkaline phosphatase [BAP]-FLAG, C-terminal; Sigma) was incubated in wells coated with sSgIGSF-Fc at several concentrations that ranged between 0.25 and 2.5 mM. mSgIGSF-ED-FLAG bound to plate-bound sSgIGSF-Fc in a dose-dependent manner, while the control protein did not bind to it at all even at the maximal concentration (Figure 4a) . The result indicated a specific and direct interaction between sSgIGSF and the mSgIGSF extracellular domain.
We wondered if sSgIGSF might inhibit homophilic binding of mSgIGSF. To examine this speculation, we performed cell aggregation assays using L cells, which Figure 4 sSgIGSF-Fc binds the extracellular domain of mSgIGSF and inhibits homophilic interactions of mSgIGSF. (a) Binding of mSgIGSF-ED-FLAG to plate-bound sSgIGSF-Fc. A plasmid vector expressing mSgIGSF-ED-FLAG was constructed by PCR using clone #8 (containing the full-length mSgIGSF) as a template with a pair of oligonucleotide primers: F, the same that used in Figure 3 ; and R, 5 0 -ATAGTTTAGCGGCCGCTCACTTGTCGTCATCGTCCTTGTAGTCTGCCCCAATGGTCCCCT-3 0 . R primer contained a FLAG (DYKDDDK) sequence and NotI site at the 5 0 end. The resulting SalI-NotI fragment was inserted into the pEFBos human IgG 1 Fc cassette (pEFBosFc; Suda and Nagata, 1994) via its SalI-NotI sites. Subsequently, mSgIGSF-ED-FLAG was produced and purified as described in Figure 3 and Kumanogoh et al. (2000) . Microtiter plate wells (Nalge Nunc) were coated for 2 h at room temperature with 50 ml of PBS containing 50 ng of sSgIGSF-Fc. The wells were blocked overnight at 41C with 100 ml of 25% Block Ace (Dainippon Pharmaceutical) in PBS and then incubated for 2 h at room temperature with 50 ml of purified mSgIGSF-ED-FLAG or BAP-FLAG (Sigma) at concentrations of 0.25-2.5 mM in PBS. The plates were then washed three times with PBS containing 0.05% Tween 20 (PBS-T) and incubated for 2 h at room temperature with 50 ml of anti-FLAG M2 monoclonal antibody (Sigma) diluted 1 : 500 in PBS containing 10% Block Ace. After extensive washing with PBS-T, the wells were incubated for 2 h at room temperature with 50 ml of peroxidase-conjugated anti-mouse IgG antibody (MBL) diluted 1 : 1000 in PBS containing 10% Block Ace, washed three times in PBS-T, and developed with 50 ml of 3,3 0 ,5,5 0 -tetramethylbenzidine (KPL). The reaction was stopped after 5 min with 50 ml of 2 N H 2 SO 4 and the optical density measured at 450 nm. The mean values of triplicate samples were plotted with bars indicating the SE. (b) Establishment of L-cell clones stably expressing mSgIGSF. The plasmid vector that expresses mSgIGSF (pCX4bsr-SgIGSF) was constructed previously (Ito et al., 2003a) . L cells were transfected with the pCX4bsr-SgIGSF vector or the empty vector, and blasticidin (3 mg/ml)-resistant clones were selected. Stable clones were lysed in a buffer containing 50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 1% Triton X-100, and 1 mM phenylmethylsulfonyl fluoride. The lysates were separated on a SDSpolyacrylamide gel and blotted with a polyclonal antibody against the C-terminal peptide of mSgIGSF (Ito et al., 2003a) (upper) . After stripping, the blot was probed with an anti-a-tubulin antibody to indicate the total amount of protein loaded per lane (Sigma) (lower). (c) Cell aggregation assay of L-cell transfectants. L-cell clones were removed from culture dishes with EDTA treatment and washed with Hank's balanced salt solution (HBSS) twice. Then the cells were passed through an 18-gauge needle three times and finally resuspended to a concentration of 2 Â 10 6 cells/ml in HBSS containing 2% FCS. Aliquots (0.5 ml) were transferred to 1.5-ml siliconized polypropylene tubes (Sarstedt) and rotated at a speed of 25 r.p.m. for 15-60 min at 371C. After the indicated time points, aggregation was quantified by examining representative aliquots from each sample on a hemocytometer grid using phase-contrast optics. The number of single cells, cells in two-cell aggregates, and cells present in aggregates containing greater than two cells were counted in four 1-mm squares. At least 400 cells were counted from each sample. The percentages of total cells present in aggregates were calculated and the mean values of triplicate samples were plotted with bars indicating the SE when larger than the symbols. ) with unlabeled cells (denoted by (À) ). For labeling, cells were cultured in DMEM containing 10% FCS and 10 mM DiI (Molecular Probe Inc., Eugene, OR, USA) for 30 min, and then were washed with HBSS three times. Singlecell suspensions of each set of cells, one labeled and the other unlabeled, were prepared as described in (c). Aliquots (0.25 ml) of each were combined in tubes and allowed to aggregate as described in (c). After the aggregation was completed, the cells were visualized using a confocal laser scanning microscope (LSM510; Carl Zeiss). In total, 30 aggregates were observed from each sample and the number of fluorescent and nonfluorescent cells in each aggregate was counted. The percentages of fluorescent cells in individual aggregates were plotted (graph). There was a significant difference between the two groups (Po0.01 by Mann-Whitney U test). (e) Dose-dependent inhibition of L mSgIGSF -cell aggregation by sSgIGSF-Fc. The sSgIGSF-Fc fusion protein was purified from a 5-L culture supernatant of a stable P3U1 plasmacytoma clone carrying pEFBosFc-sSgIGSF. This clone had been established by electroporation and G418-resistance as described previously (Kumanogoh et al., 2000) . A single-cell suspension of L mSgIGSF cells was prepared as described in (c). Aliquots (0.5 ml) were transferred to tubes that contained either sSgIGSFFc or human IgG 1 at the indicated concentrations. Cells were allowed to aggregate for 30 min and aggregation was quantified as described in (c). The mean values of triplicate samples were plotted with bars indicating the SE. *Po0.01 by t-test when compared with the values of the human IgG 1 group. (f) Specific binding of sSgIGSF-Fc to L mSgIGSF cells. Cells were allowed to aggregate for 30 min in the presence of sSgIGSF-Fc at a concentration of 50 mg/ml as described in (e). Cells were washed with PBS containing 1% bovine serum albumin and 0.1% azide (PBS/BSA/azide), and then incubated with an FITC-conjugated anti-human IgG Fc-fragment antibody (Jackson ImmunoResearch Laboratories) at a 1 : 200 dilution for 30 min at 41C. After washing the cells in PBS/BSA/azide, flow cytometry was performed using a FACScan cell analyser (Becton Dickinson) (red lines). To determine the background fluorescence intensity (dotted lines), single-cell suspensions were prepared as described in (c) and incubated with human IgG 1 at a concentration of 50 mg/ml in PBS/BSA/azide for 30 min at 41C. The remaining procedures were the same as those described above. (g) Colocalization of sSgIGSF-Fc with mSgIGSF on L mSgIGSF -cell margins. L mSgIGSF cells were grown on coverslips, fixed with methanol, and incubated with sSgIGSF-Fc (10 mg/ml) and the anti-mSgIGSF antibody (1 : 200 dilution) in PBS containing 1% BSA. After washing cells, sSgIGSF-Fc and the antibody bound to cells were stained with FITC (green) and Cy5 (red), respectively. The procedure for cell visualization was described previously (Ito et al., 2003a) . Yellow areas indicate the colocalization of FITC and Cy3 signals in the merged image. DIC, differential interference contrast do not express mSgIGSF endogenously (Figure 4b ). We established an L-cell clone (L mSgIGSF ) stably expressing exogenous mSgIGSF and a vector-control L-cell clone (L Vec ) that did not express mSgIGSF (Figure 4b) . First, the two L-cell clones were examined using standard cell aggregation assays. Single-cell suspensions of each cell type were allowed to aggregate for 15, 30, and 60 min. While only a few percent of L Vec cells aggregated in 60 min, more than half of the L mSgIGSF cells aggregated in 30 min (Figure 4c ). As previously reported for cells overexpressing mTSLC1 , the absence of Ca When L mSgIGSF cells were allowed to aggregate with each other in the presence of increasing amounts of sSgIGSF-Fc, aggregation was inhibited in a dosedependent manner (Figure 4e ). In contrast, human IgG 1 did not exhibit any inhibitory effect on aggregation even at a concentration of 50 mg/ml. After L mSgIGSF cells were allowed to aggregate in the presence of sSgIGSFFc at a concentration of 50 mg/ml, they were incubated with FITC-conjugated anti-human IgG Fc antibody and then analysed with FACScan. Most L mSgIGSF cells incubated with sSgIGSF-Fc were labeled with FITC nearly 10-fold as strongly as those incubated with human IgG 1 (Figure 4f ). To exclude nonspecific labeling, untransfected L and L Vec cells were allowed to aggregate in the presence of sSgIGSF-Fc and then analysed with FACScan. No significant FITClabeling was detectable in these cells (Figure 4f ). After L mSgIGSF cells were grown on coverslips and incubated with sSgIGSF-Fc, localization of sSgIGSF-Fc and mSgIGSF was detected immunocytochemically. Signals for sSgIGSF-Fc were well colocalized with immunostains for mSgIGSF on the cell margins (Figure 4g ). These results collectively suggest that binding of sSgIGSF-Fc to mSgIGSF results in the inhibition of the homophilic interactions of mSgIGSF. Thus, sSgIGSF appears to regulate mSgIGSF binding actions negatively.
